{
  "denotations": [
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 36,
        "end": 47
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 122,
        "end": 129
      }
    },
    {
      "id": "T4",
      "obj": "Disease",
      "span": {
        "begin": 262,
        "end": 282
      }
    },
    {
      "id": "T5",
      "obj": "Disease",
      "span": {
        "begin": 285,
        "end": 306
      }
    },
    {
      "id": "T6",
      "obj": "Disease",
      "span": {
        "begin": 312,
        "end": 318
      }
    },
    {
      "id": "T9",
      "obj": "Disease",
      "span": {
        "begin": 361,
        "end": 377
      }
    },
    {
      "id": "T7",
      "obj": "Disease",
      "span": {
        "begin": 66,
        "end": 100
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "25696877_6",
  "text": "Moreover , in patients treated with clopidogrel predominantly for percutaneous coronary intervention , carriers of 1 or 2 CYP2C19 loss-of-function alleles are at increased risk for major adverse cardiovascular outcomes , with an 1.5-fold increase in the risk of cardiovascular death , myocardial infarction , or stroke as well as an 3-fold increase in risk for stent thrombosis ."
}
